Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Recap by typeshit. Full story at Rolling Out.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Hims & Hers and a peptide academy met White House reviewers before release, and the Partnership for Safe Medicines has petitioned the FDA to block it.
Martin cautions followers that peptides being simpler to obtain is no reason to use ones that haven't been tested much.
A short social explainer from ABC7 Chicago on Lilly's experimental retatrutide and how it targets three hormones tied to appetite, with more at the station's link.
Loading…